AZTA on Nasdaq

Azenta Life Sciences

Logo: https://www.azenta.com./, Non-free logo, via Wikipedia⁴

Semiconductor Manufacturer

Azenta, (formerly Brooks Automation) was founded in 1978, and is based in Burlington, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$593.8MRevenue, fiscal 2025⁵

-$55.8MNet income, fiscal 2025⁵

Compare with Veeco, Cricut or Axcelis Technologies, or pick any stock.

TickerAZTA on Nasdaq¹
Industrybiotechnology¹
HeadquartersBurlington¹
Websitewww.azenta.com
Legal formDelaware corporation¹
Incorporated inDE⁶
Business address200 Summit Drive, 6Th Floor, Burlington, Ma 01803⁶
Filer categoryLarge accelerated filer⁶

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

45.5%Gross margin⁵

-4.5%Operating margin⁵

-9.4%Net margin⁵

3.6%Revenue growth, 2025⁵

-3.2%Return on equity⁵

$38.3MFree cash flow⁵

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Service brought in 71% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

Service$420.6M⁵71%up 5% from 2024
Product$173.2M⁵29%down 0% from 2024

Products and services by year

Products and services	2023	2024	2025
Service	$375.4M	$399.7M	$420.6M
Product	$176.1M	$173.7M	$173.2M

Business segments

Multiomics brought in 45% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

Multiomics$269.2M⁵45%up 6% from 2024
Core Products$197.6M⁵33%up 1% from 2024
Sample Repository Solutions$127.0M⁵21%up 4% from 2024

Business segments by year

Business segments	2023	2024	2025
Multiomics	$248.3M	$254.6M	$269.2M
Core Products	$192.1M	$196.5M	$197.6M
Sample Repository Solutions	$111.1M	$122.4M	$127.0M

Regions

United States brought in 61% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

United States$365.0M⁵61%down 0% from 2024
Europe$107.4M⁵18%up 13% from 2024
China$58.3M⁵10%up 0% from 2024
United Kingdom$35.4M⁵6%up 30% from 2024
Asia Pacific$23.3M⁵4%up 9% from 2024
Other$4.4M⁵1%down 32% from 2024

Regions by year

Regions	2023	2024	2025
United States	$351.4M	$365.1M	$365.0M
Europe	$87.2M	$95.2M	$107.4M
China	$52.1M	$58.2M	$58.3M
United Kingdom	$26.7M	$27.2M	$35.4M
Asia Pacific	$25.6M	$21.3M	$23.3M
Other	$8.5M	$6.5M	$4.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and admin

Cost of revenue50¢$323.5M
Research and development5¢$30.4M
Selling, general and admin40¢$261.6M
Income tax5¢$31.6M

Out of $593.8M in revenue.⁵ The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

Capital spendingKept or used elsewhere

Capital spending47¢$33.9M
Kept or used elsewhere53¢$38.3M

Out of $72.2M of cash from operations.⁵

Financial statements

Revenue⁸⁹¹⁰¹¹¹²⁵$593.8M in 2025−6% since 2018

Gross profit⁸⁹¹⁰¹¹¹²⁵$270.3M in 2025+10% since 2018

Operating income⁸⁹¹⁰¹¹¹²⁵-$26.8M in 2025

Net income⁸⁹¹⁰¹¹¹²⁵-$55.8M in 2025

Every line of the income statement in the latest annual report, as filed.⁵

Period ending	2025-09-30	2024-09-30	2023-09-30
Total revenue	$593.8M	$573.4M	$551.5M
Total cost of revenue	$323.5M	$318.8M	$312.3M
Gross profit	$270.3M	$254.6M	$239.2M
Research and development	$30.4M	$31.5M	$32.1M
Selling, general and administrative	$261.6M	$263.0M	$263.7M
Impairment of goodwill and intangible assets	$0	$4.7M	$0
Restructuring charges	$5.2M	$6.8M	$4.6M
Total operating expenses	$297.1M	$305.9M	$300.5M
Operating loss	-$26.8M	-$51.3M	-$61.2M
Interest income, net	$18.8M	$32.9M	$43.5M
Other income (expense), net	$922.0K	-$732.0K	-$2.3M
Loss from continuing operations before income taxes	-$7.1M	-$19.1M	-$20.0M
Income tax (benefit) expense	-$31.6M	$5.2M	-$12.0M
Income (loss) from continuing operations	$24.5M	-$24.4M	-$8.0M
Loss from discontinued operations, net of tax	-$80.2M	-$140.5M	-$6.6M
Net loss	-$55.8M	-$164.9M	-$14.6M
Income (loss) from continuing operations (in dollars per share)	$1	-$0	-$0
Loss from discontinued operations, net of tax (in dollars per share)	-$2	-$3	-$0
Net loss per share (in dollars per share)	-$1.22	-$3.10	-$0.22
Income (loss) from continuing operations (in dollars per share)	$1	-$0	-$0
Loss from discontinued operations, net of tax (in dollars per share)	-$2	-$3	-$0
Diluted net loss per share (in dollars per share)	-$1.22	-$3.10	-$0.22
Basic (in shares)	45.7M shares	53.2M shares	66.3M shares
Diluted (in shares)	45.9M shares	53.2M shares	66.3M shares

Total assets¹⁶⁸⁹¹⁰¹¹⁵$2.1B in 2025+88% since 2018

Total liabilities¹⁶⁸⁹¹⁰¹¹¹²⁵$332.6M in 2025−12% since 2018

Shareholders’ equity⁹¹²⁵$1.7B in 2025+141% since 2018

Cash⁸⁹¹⁰¹¹¹²⁵$279.8M in 2025+42% since 2018

Long-term debt¹⁶⁸⁹¹⁰$49.7M in 2021−74% since 2018

Every line of the balance sheet in the latest annual report, as filed.⁵

Period ending	2025-09-30	2025-06-30	2025-03-31
Cash and cash equivalents	$279.8M
Short-term marketable securities	$61.1M
Accounts receivable, net of allowance for expected credit losses ($4,649 and $5,349, respectively)	$142.2M		$146.9M
Inventories	$75.0M	$80.8M	$75.2M
Short-term restricted cash	$2.4M
Refundable income taxes	$9.7M
Prepaid expenses and other current assets	$64.7M	$74.8M	$67.2M
Current assets held for sale	$73.5M		$90.7M
Total current assets	$708.3M	$678.3M	$710.4M
Property, plant and equipment, net	$154.0M
Long-term marketable securities	$201.6M
Long-term deferred tax assets	$726.0K
Operating lease right-of-use assets	$54.0M
Goodwill	$702.4M
Intangibles assets, net	$101.8M
Long term income taxes receivable	$45.6M
Other assets	$6.1M		$7.1M
Noncurrent assets held for sale	$85.0M		$133.3M
Total assets	$2.1B	$2.0B	$2.0B
Accounts payable	$37.7M	$38.3M	$39.3M
Deferred revenue	$31.6M
Derivative liability	$33.4M
Accrued warranty and retrofit costs	$4.7M
Accrued compensation and benefits	$35.8M	$32.0M	$26.3M
Accrued customer deposits	$26.5M
Accrued income taxes payable	$9.4M	$8.8M	$10.2M
Accrued expenses and other current liabilities	$30.3M
Current liabilities held for sale	$28.3M
Total current liabilities	$237.7M	$246.2M	$221.0M
Long-term deferred tax liabilities	$18.2M	$20.3M	$22.3M
Long-term operating lease liabilities	$51.2M
Other long-term liabilities	$11.1M
Noncurrent liabilities held for sale	$14.3M		$31.0M
Total liabilities	$332.6M	$346.0M	$338.6M
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding	$0
Common stock, $0.01 par value - 125,000,000 shares authorized, 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025, 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024	$594.0K
Additional paid-in capital	$529.6M	$524.2M
Accumulated other comprehensive loss	-$22.2M	-$19.9M	-$42.2M
Treasury stock, at cost - 13,461,869 shares at September 30, 2025 and September 30, 2024	-$201.0M
Retained earnings	$1.4B	$1.4B	$1.4B
Total stockholders' equity	$1.7B	$1.7B	$1.7B
Total liabilities and stockholders' equity	$2.1B	$2.0B	$2.0B
Allowance for Doubtful Accounts Receivable, Current	$4.6M
Preferred stock, par value (in dollars per share)	$0.01
Preferred stock, authorized (in shares)	1.0M shares
Preferred stock, issued (in shares)	0 shares
Preferred stock, outstanding (in shares)	0 shares
Common stock, par value (in dollars per share)	$0.01
Common stock, authorized (in shares)	125.0M shares
Common stock, issued (in shares)	59.3M shares
Common stock, outstanding (in shares)	45.9M shares
Treasury stock, shares (in shares)	13.5M shares

Cash from operations⁸⁹¹⁰¹¹¹²⁵$72.2M in 2025−2% since 2018

Capital spending⁸⁹¹⁰¹¹¹²⁵$33.9M in 2025+165% since 2018

Free cash flow⁸⁹¹⁰¹¹¹²⁵$38.3M in 2025−37% since 2018

Dividends paid⁸⁹¹⁰¹¹¹²$0 in 2024

Share buybacks¹²⁵$0 in 2025

Every line of the cash flow in the latest annual report, as filed.⁵

Period ending	2025-09-30	2024-09-30	2023-09-30
Net loss	-$55.8M	-$164.9M	-$14.6M
Depreciation and amortization	$61.2M	$90.7M	$85.6M
Impairment of goodwill and intangible assets	$0	$116.0M	$0
Loss on assets held for sale	$93.1M	$0	$0
Property, plant and equipment and other asset write-offs	$3.5M	$4.4M	$0
Inventory write-downs	$0	$3.3M	$0
Other non-cash charges related to restructuring and transformation	$0	$4.3M	$0
Stock-based compensation	$20.9M	$14.5M	$9.4M
Contingent consideration adjustment	$0	$0	-$18.5M
Amortization and accretion on marketable securities	-$1.6M	-$6.0M	-$7.9M
Deferred income taxes	-$27.0M	-$15.9M	-$28.7M
Purchase accounting impact on inventory	$0	$0	$9.7M
Loss on disposals of property, plant and equipment	$711.0K	$296.0K	$43.0K
Accounts receivable	$21.0M	-$12.1M	$34.5M
Inventories	-$2.7M	$15.9M	$8.3M
Accounts payable	$1.0M	$9.2M	-$14.7M
Deferred revenue	$641.0K	-$3.6M	-$7.6M
Accrued warranty and retrofit costs	-$435.0K	-$684.0K	$4.6M
Accrued compensation and tax withholdings	$7.4M	-$2.8M	-$19.1M
Long term income taxes receivable	-$45.6M	$0	$0
Other assets and liabilities	-$4.3M	-$3.0M	-$35.0M
Net cash provided by operating activities	$72.2M	$49.7M	$5.8M
Purchases of property, plant and equipment	-$33.9M	-$37.4M	-$39.4M
Purchases of marketable securities and other investments	-$451.4M	-$405.6M	-$236.2M
Sales and maturities of marketable securities	$389.5M	$666.2M	$1.1B
Proceeds from other investment	$2.1M	$0	$0
Net investment hedge settlement	$3.2M	$1.5M	$29.3M
Acquisitions, net of cash acquired	$0	$0	-$386.5M
Net cash (used in) provided by investing activities	-$90.5M	$224.7M	$431.4M
Proceeds from issuance of common stock	$2.8M	$3.3M	$3.6M
Payments of finance leases	-$985.0K	-$783.0K	-$578.0K
Withholding tax payments on net share settlements on equity awards	$0	$0	-$5.0M
Share repurchases	$0	-$661.7M	-$838.5M
Excise tax payment for settled share repurchases	-$11.4M	$0	$0
Net cash used in financing activities	-$9.6M	-$659.2M	-$840.5M
Effects of exchange rate changes on cash, cash equivalents and restricted cash	$3.6M	$21.7M	$46.0M
Net decrease in cash, cash equivalents and restricted cash	-$24.3M	-$363.1M	-$357.3M
Cash paid for income taxes, net	$6.6M	$2.7M	$43.1M
Purchases of property, plant and equipment included in accounts payable and accrued expenses	$5.5M	$2.8M	$2.7M

Compare Azenta Life Sciences with another company

The story

Brooks Automation was set up in 1978, and incorporated in 1994.

Brooks acquired the German company Jenoptik-Infab GmbH, subsidiary of M+W Zander, in 1999 to incorporate its mini-environment technology for 300 mm wafer handling.

In 2002, Brooks Automation, Inc. completed the acquisition of Intelligent Automation Systems, Inc. of Cambridge, Massachusetts, a custom automation company with technology and products for the semiconductor, photonics and life sciences industries.

Brooks Automation acquired the Celigo automated Cell Cytometer product line from Cyntellect, Inc in 2011. The same year, Brooks acquired Nexus Biosystems, which produced compound and sample management systems. The following year the company acquired intangible assets from Intevac, Inc. and acquired Crossing Automation Inc.

In October 2012, Brooks Automation entered into an agreement to acquire Crossing Automation Inc.

In April 2014, Brooks Automation entered into an agreement to sell its Granville-Phillips division to MKS Instruments.

Brooks closed the sale of Granville-Phillips to MKS Instruments on May 30, 2014.

Brooks automation announced the acquisition of Biostorage Technologies on 1 December 2015.

Read the full text

In 2017, Brooks acquired 4titude, a maker of scientific tools and consumables, while in 2018, Brooks acquired GENEWIZ, a genomics services provider as part of their life sciences division's expansion.

In November 2021, Brooks Automation Inc. split into two entities, Brooks Automation and Azenta Life Sciences. The latter will focus exclusively on their life science division.

In August 2022, Azenta Life Sciences has come to a definitive agreement to acquire B Medical Systems S.á.r.l., in a transaction of approx. €410 million (with an additional €50 million in future performance milestones) is expected to be completed by October 2022.

From Wikipedia’s article on Azenta, shared under CC BY-SA 4.0.⁷

Products and brands

multi-well plate

Listed on Wikidata.¹

Business

Brooks Automation operates in three segments: Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems.

Brooks Automation provides mainly four kinds: semiconductor automation and life science systems equipment, gas analysis and vacuum measurement, cryopumps, cryochillers and compressors, asset tracking equipment. The company features in developing and building the handling system and related technology. Automation products are used to support both atmospheric and vacuum based processes while the company's focus remains on improving performance and productivity. The company provides vacuum pumps and instrumentation to maintain pressure consistency of the known process gas. The Brooks Life Science Systems provides automated sample management systems and equipment, such as automated blood fractionation equipment, cellular imaging, and consumables parts.

Research and development

In January 2012, Brooks Automation announced that it had acquired the Celigo Cell Cytometer product line from Cyntellect Inc. Celigo had an advantage in cell imaging systems based on its unique combination of high-throughput, ease-of-use, and affordability.

In April 2012, Brooks Automation announced the Polycold Systems XC Cryochiller (a multi-purpose cooler) product line and set a new standard in the industry. With the new production line put into use in vacuum and thermal management applications, it would greatly increase water vapor pumping speed and decrease the operating costs.